Extracellular vesicle‑mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro

Oncol Rep. 2023 Nov;50(5):194. doi: 10.3892/or.2023.8631. Epub 2023 Sep 21.

Abstract

Extracellular vesicles (EVs) produced by various cells, including tumor cells, carry biomolecules to neighboring cells. In hepatocellular carcinoma (HCC), adenosine to inosine RNA editing of antizyme inhibitor 1 (AZIN1), specifically regulated by adenosine deaminase acting on RNA‑1 (ADAR1), promotes carcinogenesis. The present study examined if EVs and ADAR1 in the EVs released from HCC cells are transferred to neighboring cells in co‑culture systems and reporter assay. Distribution of the ADAR1 expression in human tissues were examined by immunohistochemistry. EVs released from HCC cells containing ADAR1 were delivered to neighboring HCC cells and non‑cancerous hepatocytes. The increased ADAR1 protein levels resulted in serine to glycine substitution at residue 367 of AZIN1, which augmented transformation potential and increased aggressive behavior of cancer cells. In clinically resected samples, ADAR1 distribution was highly heterogeneous within the tumor specimen and denser in non‑cancerous tissue surrounding the HCC tissue. These observations suggested that ADAR1 protein may be delivered from HCC cells to neighboring cells via EVs and that EV‑mediated RNA editing may serve a pivotal role in determining HCC heterogeneity and spread.

Keywords: ADAR1; AZIN1; EV; RNA editing; tumor heterogeneity.

MeSH terms

  • Carcinoma, Hepatocellular* / genetics
  • Extracellular Vesicles* / genetics
  • Hepatocytes
  • Humans
  • Liver Neoplasms* / genetics
  • RNA Editing / genetics

Grants and funding

The present study was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant nos. #20J20625, #22H02828, #22K15958 and #21H02893), Japan Society of Technology Core Research for Evolutionary Science and Technology (grant no. #JPMJCR19H5) and Research Program on Hepatitis from Japan Agency for Medical Research and Development (grant nos. JP23fk0210092 and JP23fk0310506).